Asterias Biotherapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Biotime Inc's Asterias Biotherapeutics Inc. files registration statement for underwritten public offering
Biotime Inc:Says Asterias Biotherapeutics Inc., a subsidiary of BioTime Inc. has filed a registration statement with the Securities and Exchange Commission for an underwritten public offering of up to $15,000,000 of units with each unit consisting of one share of Series B common stock and one redemption right.Says shares of Series B common stock and redemption rights will immediately be freely tradable as separate securities.Says number of units to be sold and the price range for the proposed offering have not yet been determined.Says offering will be made through Burrill Securities LLC.Says Asterias plans to use the net proceeds of the offering to fund its product development programs and for working capital.Says Asterias intends to apply to list the Series B common stock on the NYSE MKT under the symbol AST.
Latest Developments for Asterias Biotherapeutics Inc
Latest Key Developments in Biotechnology
- Akers Biosciences Inc announces joint venture to market rapid diagnostic tests in China
- Rich Pharmaceuticals Inc announces submission of IND application to FDA for treatment of acute myelocytic leukemia and myelodysplastic syndrome
- Celator Pharmaceuticals Inc prices $12.9 mln public offering of common stock and warrants to purchase common stock
- TAKARA BIO INC amends consolidated mid-year outlook for FY 2015
- Share this
- Digg this